MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)

This study has been terminated.
Sponsor:
Information provided by:
Genaera Corporation
ClinicalTrials.gov Identifier:
NCT00094120
First received: October 11, 2004
Last updated: January 8, 2008
Last verified: November 2007
  Purpose

Age-Related Macular Degeneration (AMD) is a degenerative disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula.

Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine when administered with verteporfin therapy in patients with "wet" AMD.


Condition Intervention Phase
Macular Degeneration
Drug: MSI-1256F (Squalamine Lactate)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Safety and Efficacy of MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)

Resource links provided by NLM:


Further study details as provided by Genaera Corporation:

Estimated Enrollment: 60
Study Start Date: October 2004
Study Completion Date: February 2007
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with a diagnosis of "wet" age-related macular degeneration

Exclusion Criteria:

  • Prior treatment for "wet" age-related macular degeneration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00094120

Locations
United States, Pennsylvania
Genaera Corporation
Plymouth Meeting, Pennsylvania, United States, 19462
Sponsors and Collaborators
Genaera Corporation
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00094120     History of Changes
Other Study ID Numbers: MSI-1256F-208
Study First Received: October 11, 2004
Last Updated: January 8, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Genaera Corporation:
Age-Related Macular Degeneration - Wet Type

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Squalamine
Verteporfin
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Photosensitizing Agents
Radiation-Sensitizing Agents
Dermatologic Agents

ClinicalTrials.gov processed this record on July 28, 2014